The extent of coronary stenosis and the level of antibodies to atherogenic lipoproteins in patients with coronary heart disease
- Authors: Urazgil'deeva S.A.1, Titkov A.Y.2, Vasina L.V.2, Tsaregorodtseva V.V.1, Gurevich V.S.1, Urazgildeeva SA3, Titkov AY.4, Vasina LV4, Tsaregorodtseva VV3, Gurevich VS3
-
Affiliations:
- ГОУ ВПО СПбГМА им. И. И. Мечникова Росздрава
- ФГУЗ Клиническая больница № 122 им. Л. Г. Соколова ФМБА РФ
- I.I. Mechnikov State Medical Academy, Center for Atherosclerosis and Lipid Disorders, St-Petersburg
- L.G. Sokolov city hospital № 122, St-Petersburg
- Issue: Vol 83, No 9 (2011)
- Pages: 10-13
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/30887
- ID: 30887
Cite item
Full Text
Abstract
Material and methods. Sixty CHD patients were examined for titer of anti-OLDL, levels of total cholesterol (TC), LDLP cholesterol, HDLP cholesterol, triglycerides. Selective coronarography (SC) was made on demand.
Results. Elevated titer of anti-OLDL was found only in 12 examinees. It was significantly lower in CHD women than in men. No significant differences by anti-OLDL were found in CHD patients with and without significant risk factors. SC registered in all CHD examinees local stenosis of different severity. Stenosis in 3 coronary arteries was detected in 31 cases, in 2 coronary arteries - in 14, in 1 coronary artery - in 15 patients, most frequently the affection was located in the diagonal branch of the left coronary artery. Stenosis of the left coronary artery trunk was diagnosed in one case. The correlation analysis revealed a strongly significant positive correlation between content of anti-OLDL and the degree of CS.
Conclusion. The level of anti-OLDL in CHD patients directly correlates with the degree of CS and is a marker of coronary atherosclerosis severity.
About the authors
Soreyya Asafovna Urazgil'deeva
ГОУ ВПО СПбГМА им. И. И. Мечникова Росздрава
Email: s_urazgildeeva@hotmail.com
Кафедра кардиологии- канд. мед. наук, доц. каф. кардиологии ФПК ГОУВП СПбМА им. И. И. Мечникова; консультант Центра атеросклероза и нарушений липидного обмена ФГУЗ клиническая больница № 122 им. Л. Г. Соколова, тел./ факс 8-812-559-97-59; ГОУ ВПО СПбГМА им. И. И. Мечникова Росздрава
Aleksandr Yur'evich Titkov
ФГУЗ Клиническая больница № 122 им. Л. Г. Соколова ФМБА РФ
Email: alextitkov76@mail.ru
канд. мед. наук, зав. отд-нием рентгеноэндоваскулярной хирургии и интервенционной кардиологии ВГУЗ клиническая больница № 122 им. Л. Г. Соколова, тел.: 8-812-558-94-68; ФГУЗ Клиническая больница № 122 им. Л. Г. Соколова ФМБА РФ
Lyubov' Vasil'evna Vasina
ФГУЗ Клиническая больница № 122 им. Л. Г. Соколова ФМБА РФ
Email: lubov.vasina@gmail.com
д-р мед. наук, врач-лаборант биохимической лаб. ФГУЗ клиническая больница № 122 им. Л. Г. Соколова, тел.: 8-812-558-94-68; ФГУЗ Клиническая больница № 122 им. Л. Г. Соколова ФМБА РФ
Viktoriya Vital'evna Tsaregorodtseva
ГОУ ВПО СПбГМА им. И. И. Мечникова Росздрава
Email: vika.ru@rambler.ru
Кафедра кардиологии- клинический ординатор каф. кардиологии ФПК ГОУВП СПбГМА им. И. И. Мечникова; ГОУ ВПО СПбГМА им. И. И. Мечникова Росздрава
Viktor Savel'evich Gurevich
ГОУ ВПО СПбГМА им. И. И. Мечникова Росздрава
Email: ater@med122.com
Кафедра кардиологии- д-р мед. наук, проф. каф. кардиологии ФПК ГОУВП СПбГМА им. И. И. Мечникова, рук. Центра атеросклероза и нарушений липидного обмена ФГУЗ клиническая больница № 122 им. Л. Г. Соколова; ГОУ ВПО СПбГМА им. И. И. Мечникова Росздрава
S A Urazgildeeva
I.I. Mechnikov State Medical Academy, Center for Atherosclerosis and Lipid Disorders, St-PetersburgI.I. Mechnikov State Medical Academy, Center for Atherosclerosis and Lipid Disorders, St-Petersburg
A Yu Titkov
L.G. Sokolov city hospital № 122, St-PetersburgL.G. Sokolov city hospital № 122, St-Petersburg
L V Vasina
L.G. Sokolov city hospital № 122, St-PetersburgL.G. Sokolov city hospital № 122, St-Petersburg
V V Tsaregorodtseva
I.I. Mechnikov State Medical Academy, Center for Atherosclerosis and Lipid Disorders, St-PetersburgI.I. Mechnikov State Medical Academy, Center for Atherosclerosis and Lipid Disorders, St-Petersburg
V S Gurevich
I.I. Mechnikov State Medical Academy, Center for Atherosclerosis and Lipid Disorders, St-PetersburgI.I. Mechnikov State Medical Academy, Center for Atherosclerosis and Lipid Disorders, St-Petersburg
References
- Климов А. Н. Аутоиммунная теория атерогенеза и концепция модифицированных липопротеидов. Вестн. АМН СССР 1990; 11: 30-36.
- Sherer Y., Pauletto P., Shoenfeld Y. Atherosclerosis and Autoimmunity. Handbook of Systemic Autoimmune Disease.In: Doria A., Pauletto P. eds. The heart in systemic autoimmune diseases. Amsterdam. 2004. 89-95.
- Fitzgibbon G. M., Burggraf G. W., Groves T. D., Parker J. O. A double Master's two-step test: clinical, angiographic and hemodynamic correlation. Ann. Intern. Med. 1971; 74 (4): 509- 517.
- Friedwald W. T., Levy R. I., Fredrickson D. S. Estimation of the concentration of low density lipoprotein cholesterol in lasma without use of the preparative uitracentrifuge. Clin. Chem. 1972; 18 (6): 499-502.
- Насонов Е. Л., Алекберова З. С., Калашникова Л. А. и др. Антифосфолипидный синдром (синдром Hughes); 10 лет изучения в России. Клин. мед. 1998; 2: 4-11.
- Sherer Y., Shoenfeld Y. Antiphospholipid syndrome, antiphospholipid antibodies and atherosclerosis. Curr. Atheroscler.Rep. 2001; 3 (4): 328-333.
- Hamsten A., Norberg R., Bjorkholm M. et al. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet 1986; 1 (8473): 113-116.
- Насонов Е. Л., Карпов Ю. А., Алекберова З. С. и др. Антифосфолипидный синдром: кардиологические аспекты. Тер. арх. 1993; 11: 80-86.
- Holvoet P., Collen D. Oxidized lipoproteins in atherosclerosis and thrombosis. FASEB J. 1994; 8 (15): 1279-1284.
- Vaarala O. Antibodies to oxidized LDL. Lupus 2000; 9 (3): 202-205.
- Гуревич В. С., Уразгильдеева С. А., Шатилина Л. В. и др. Изменение уровней антител к окисленным липопротеидам при применении аторвастатина у женщин с ишемической болезнью сердца в постменопаузе. Кардиология 2004; 4: 76-77.
- Maggy E., Perani G., Falaschi F. et al. Autoantibodies against oxidized low density lipoproteins in patients with coronary disease. Presse Med. 1994; 23 (25): 1158-1162.
- Erkkila F. T., Narvanen O., Lehto S. et al. Autoantibodies against oxidized low density lipoproteins and cardiolipin in patients with coronary heart disease. Arterioscler. Thromb. Vase. Biol. 2000; 20 (1): 204-209
- Lehtimaki T., Lehtinen S., Solakivi T. et al. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler. Thromb. Vase. Biol. 1999; 19 (1): 23-27.
- Puuronen M., Manttari M., Manninen V. et al. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch. Intern. Med. 1994; 154 (22): 2605-2609.
- Wu R., Nityanand S., Berglund L. et al. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler. Thromb. Vase. Biol. 1997; 17 (11): 3159-3163.
- George J., Harats D., Bakshi E. et al. Anti-oxidized ow density lipoprotein antibody determination as a predictor of restenosis following percutaneous transluminal coronary angioplasty. Immunol.Lett. 1999; 68 (2-3): 263-266.
- Morton K. E., Gavaghan T. P., Krilis S. A. et al. Coronary artery bypass graft failure - an autoimmune phenomenon? Lancet 1986; 2 (8520): 1353-1357.
- Nilsson J., Regnstrom J., Frostegard J., Stiko A. Lipid oxidation and atherosclerosis. Herz 1992; 17 (5): 263-269.
![](/img/style/loading.gif)